DGX Quest Diagnostics Inc. Company Net Income

Official company branding of Quest Diagnostics Incorporated (DGX)

Quest Diagnostics aims for diagnostic dominance by acquiring loss-making centers and implementing AI genetics. The GURU.Markets service features a linear chart of the company's gross profit, where the current status is 1.13. The robotization of data analysis minimizes routine tasks, although sample collection remains manual. The environmental focus is based on logistics optimization and the safe disposal of chemicals.

Company Net Income: Quest Diagnostics (DGX) for 07/04/2022 - 10/29/2026

Analytical breakdowns and data insights for company Quest Diagnostics Incorporated (DGX)

- market value and analyst target forecast:
Stock Price Quest Corp|DGX - Price Target Chart
- market capitalization data:
Market Value Quest Corp|DGX - Real Price to Acquire Entire Company
- book capitalization indicators:
Net Asset Value per Share Quest Diagnostics|DGX - Company Book Value|Market Capitalization to Book Value questdiagnostics.com|DGX - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Quest Diagnostics|DGX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Quest Diagnostics Inc.|DGX - Company Debts|Debt to Net Assets Quest Corp|DGX - Company Long-Term Liabilities|Company Short-Term Debts Quest Diagnostics|Immediate Liquidity questdiagnostics.com
- company profitability and valuation multiples indicators:
DGX - Company Net Income
Basic company analysis:DGX (Quest Corp)
Mass-produced product of Quest

Molecular oncology tests and strategic alliances with clinics ensure the stability of Quest Diagnostics (DGX). This indicator captures daily net profit, providing a real-time assessment of the impact of costs on margins prior to the publication of official reports. An analysis of the company's net cash flow allows for an evaluation of the business's actual resilience. Short-term fluctuations here are technical in nature. Current price action confirms the fundamental stability and fair market value of the asset.

Key competitors

Agilent Corp (A) - Net Profit|Company Net Income Illumina, Inc.|Company Net Income EXAS|Net Income RVTY (Revvity)|BIO - Company Net Income|Company Net Income Anbio Tech NNNN|Net Financial Result Nordion (SHC)|QuidelOrtho - Net Profit|Net Financial Result opko.com OPK|CareDx Corp (CDNA) - Company Net Income|MRVI - Net Financial Result|Company Net Income Fulgent Corp|LAB - Annual Net Income|Net Income CTKB (Cytek Biosciences, Inc.)|Net Profit orasure.com (OSUR)|Net Profit XGN (Exagen)|MDxHealth S.A. (MDXH) - Company Net Income|LUCD - Company Net Income|Net Financial Result Prenetics Global PRE|IMDX (imdxinc.com) - Net Income|TRIB: Profit After Payment of Taxes|Net Income PRPH|AIMD: Final Profit|Net Profit CODX|Heart Test Labs - Company Profit|Net Profit BMRA (Biomerica, Inc.)|Net Financial Result Cardio Diagnostics Holdings Inc. (CDIO)|Virax Biolabs - Net Profit|BJDX - Net Profit|AWH: Net Profit|Annual Net Income Accelerate Diagnostics Inc AXDX|Company Net Income Centogene|Company Profit ENZ (Enzo)|Company Net Income Fresh2 Group Limited (FRES)|GENE - Company Net Income|Company Net Income 23andMe Inc. ME|Net Financial Result Psychemedics Inc (PMD)